LCM
SAGE

Legato Capital Management’s Sage Therapeutics SAGE Stock Holding History

Legato Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,675
Closed -$441K – 200
2017
Q4 		$441K Buy
+2,675
New +$259K 0.06% 217

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Legato Capital Management's SAGE Position: Q1 2018 in Review

Legato Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2018, closing a stake of 2,675 shares — an estimated $441K sold.

Legato Capital Management first reported a position in SAGE in Q4 2017 and held it in 1 quarter. The position peaked at $441K in Q4 2017. 250 funds tracked by Wall St. Rank hold SAGE as of Q1 2018.

  • Legato Capital Management reported no remaining Sage Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Legato Capital Management sold 2,675 Sage Therapeutics shares in Q1 2018, an estimated $441K.
  • Legato Capital Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 1 quarter.
  • Legato Capital Management's Sage Therapeutics position peaked at $441K in Q4 2017.
  • 250 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2018.

Based on Legato Capital Management's 13F filing for Q1 2018, filed 19 Apr 2018.